Obesity, chronic kidney disease and cardiovascular risk

被引：0

作者：

Torguet Escuder, P. ^{[1
]}

机构：

[1] Hosp Univ Dr J Trueta, Serv Nefrol, Girona, Spain

来源：

HIPERTENSION Y RIESGO VASCULAR | 2021年 / 38卷 / 02期

关键词：

METABOLIC SYNDROME;

D O I：

10.1016/j.hipert.2021.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：53 / 55

页数：3

共 24 条

[1] Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice
Andres-Hernando, Ana
Lanaspa, Miguel A.
Kuwabara, Masanari
Orlicky, David J.
Cicerchi, Christina
Bales, Elise
Garcia, Gabriela E.
Roncal-Jimenez, Carlos A.
Sato, Yuka
Johnson, Richard J.
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 317 (04) : F941 - F948
[2] Progress and challenges in anti-obesity pharmacotherapy
Bessesen, Daniel H.
Van Gaal, Luc F.
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (03) : 237 - 248
[3] Effects of weight loss on renal function in obese CKD patients: a systematic review
Bolignano, Davide
Zoccali, Carmine
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 82 - 98
[4] Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium
Chang, Alex R.
Grams, Morgan E.
Ballew, Shoshana H.
Bilo, Henk
Correa, Adolfo
Evans, Marie
Gutierrez, Orlando M.
Hosseinpanah, Farhad
Iseki, Kunitoshi
Kenealy, Timothy
Klein, Barbara
Kronenberg, Florian
Lee, Brian J.
Li, Yuanying
Miura, Katsuyuki
Navaneethan, Sankar D.
Roderick, Paul J.
Valdivielso, Jose M.
Visseren, Frank L. J.
Zhang, Luxia
Gansevoort, Ron T.
Hallan, Stein I.
Levey, Andrew S.
Matsushita, Kunihiro
Shalev, Varda
Woodward, Mark
Astor, Brad
Appel, Larry
Greene
Chen, Teresa
Chalmers, John
Woodward, Mark
Arima, Hisatomi
Perkovic, Vlado
Yatsuya, Hiroshi
Tamakoshi, Koji
Li, Yuanying
Hirakawa, Yoshihisa
Coresh, Josef
Matsushita, Kunihiro
Grams, Morgan
Sang, Yingying
Polkinghorne, Kevan
Chadban, Steven
Atkins, Robert
Levin, Adeera
Djurdjev, Ognjenka
Dam, Beaver
Klein, Ron
Klein, Barbara
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2019, 364
[5] Anthropomorphic Measurements That Include Central Fat Distribution Are More Closely Related with Key Risk Factors than BMI in CKD Stage 3
Evans, Philip D.
McIntyre, Natasha J.
Fluck, Richard J.
McIntyre, Christopher W.
Taal, Maarten W.
[J]. PLOS ONE, 2012, 7 (04):
[6] A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population
Garofalo, Carlo
Borrelli, Silvio
Minutolo, Roberto
Chiodini, Paolo
De Nicola, Luca
Conte, Giuseppe
[J]. KIDNEY INTERNATIONAL, 2017, 91 (05) : 1224 - 1235
[7] Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, Hiddo J. L.
Stefansson, Bergur V.
Correa-Rotter, Ricardo
Chertow, Glenn M.
Greene, Tom
Hou, Fan-Fan
Mann, Johannes F. E.
McMurray, John J. V.
Lindberg, Magnus
Rossing, Peter
Sjostrom, C. David
Toto, Roberto D.
Langkilde, Anna-Maria
Wheeler, David C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) : 1436 - 1446
[8] Obesity-related glomerulopathy: An emerging epidemic
Kambham, N
Markowitz, GS
Valeri, AM
Lin, J
D'Agati, VD
[J]. KIDNEY INTERNATIONAL, 2001, 59 (04) : 1498 - 1509
[9] Kovesdy CP, 2017, KIDNEY DIS-BASEL, V3, P33, DOI [10.1159/000452965, 10.1556/2060.104.2017.1.9]
[10] 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
le Roux, Carel W.
Astrup, Arne
Fujioka, Ken
Greenway, Frank
Lau, David C. W.
Van Gaal, Luc
Ortiz, Rafael Violante
Wilding, John P. H.
Skjoth, Trine V.
Manning, Linda Shapiro
Pi-Sunyer, Xavier
[J]. LANCET, 2017, 389 (10077) : 1399 - 1409

← 1 2 3 →